TBI 1201 / Takara - LARVOL DELTA

Investigator Initiated Phase 1 Study of TBI-1201 (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Mie University; Recruiting ➔ Completed; N=12 ➔ 18; Trial primary completion date: Jun 2018 ➔ Mar 2021

Enrollment change • Trial completion • Trial primary completion date • Gene Therapies • Oncology • Solid Tumor • MAGEA4

Investigator Initiated Phase 1 Study of TBI-1201 (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Mie University; Trial primary completion date: Feb 2017 ➔ Dec 2017

Trial primary completion date • Biosimilar • Oncology • Solid Tumor

Medigene provides results for fiscal year 2019 and outlook (GlobeNewswire) - “bluebird bio announced its intention to start clinical development of the MAGE-A4 TCR-T candidate in 2020; By the end of 2020, Medigene expects to complete dosing of the first three dose cohorts in the dose-escalation part of the Phase I/II trial of MDG1011 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM); In 2020, Medigene will continue to work on further developing its T cell enhancers, characterizing new TCR candidates and collecting preclinical data for future clinical TCR-T trials, especially targeting solid tumor indications.”

Enrollment status • New trial • Preclinical

bluebird bio’s analyst day highlights commercial path to patients and research engine focused on next-generation gene and cell therapies (Businesswire) - "MAGE-A4: Through its collaboration with Medigene, bluebird has developed a next-generation MAGE-A4 TCR expected to enter the clinic for solid tumors in 2020."

New trial